(Date:10/10/2008)...LE, PA The American Nurses Credentialing Center (...) as a Magnet hospital. The news came via a confer...taff who broke out with cheers and applause., GMC...itals and only 294 hospitals in the United States... hospitals are eligible for this recognition., "A...
(Date:10/10/2008)...ggests poor self-care partly to blame , ,...f Medicare beneficiaries who have diabetes, being ... according to a new study. , Publishing in th...l Medicine , researchers from the University of Wa...erage age of 75.6 years) who had diabetes and were...
(Date:10/10/2008)... Honoring excellence in the imple... Healthcare Information and Management Systems Soc...Davies Awards in the Organizational, Ambulatory an... Chicago, IL (PRWEB) October 1...on of electronic health records (EHRs), the Healt...
(Date:10/10/2008)...YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins Un...ultimedia educational program,"Optimizing Adjuvan...atment,Selection," to present recent key research ...ment., In recent years, advancements in the treat... and biologic treatment combinations that are,incr...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2(Date:10/8/2008)...ovement in patients with pulmonary arterial h... have limited benefit for this debilitating, ...ease, -- Imatinib mesylate, available as Gleeve...to inhibit protein associated with PAH, -- Nova...late in PAH in 2009 EAST HANOVER, N.J., Oct....
(Date:10/7/2008)...e Texas Cardiac Arrhythmia,Institute (TCAI) at St....f,only a few sites in the nation to participate in...o treat persistent atrial fibrillation. TCAI, an,i...er specializing in heart,rhythm disorders, is a pa...exas Cardiovascular Consultants., "This is just a...
(Date:10/7/2008)...l/ -- CEL-SCI Corporation,(NYSE: CVM ) announced ...,Agreement (MTA) with the National Institutes of H...f Dr. Francesco M. Marincola, M.D., to,investigate...environment,caused by CEL-SCI,s cancer drug Multik...Disease and Immunogentics Section, Department of T...
(Date:10/7/2008)... Taligen Therapeutics Inc.,today announced that in...ndidates were presented at the XXII International ...a highlighted the candidates, efficacy in,several ...These highlighted presentations, as well as severa...veal the deep expertise and expanding,knowledge ba...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4EPA Reaches Agreement With American Energy on Clean Air Violations 16725 1St Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia 16723 1St Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia 16723 2St Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia 16723 3CCA Industries Inc Announces First Quarter Results 16721 1CCA Industries Inc Announces First Quarter Results 16721 2Veterinary Pet Insurance Launches National Pet Parents Day 16719 1Veterinary Pet Insurance Launches National Pet Parents Day 16719 2... 8, 2007 - Late-breaking Phase III,clinical trial ...ety on Thrombosis and Haemostasis (ISTH) Congress ...uperior efficacy in the,prevention of venous throm...cement surgery in a head-to-head comparison with,e...in the RECORD3,(REgulation of Coagulation in major...
...ess with Positive Phase IIa Clinical,Trial Results...lication of Key,Product in AM-Pharma,s Pipeline , ...V., the,biopharmaceutical company developing novel... diseases, today announced the positive,clinical r...trial,for patients with ulcerative colitis, a chro...
Other Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: